在多种恶性肿瘤的诊疗水平得到显著提升的今天，胰腺癌的治疗仍然是一个举步维艰的临床问题, 如何实现治疗效果上的重大突破是国内外肿瘤领域面临的一个严峻挑战，靶向给药途径为胰腺癌的治疗带来新的希望。本项目拟通过化学修饰方法将超微超顺磁性氧化铁颗粒（USPIO）、抗EGFR多肽片段和非特异性肿瘤化疗药物Gemcitabine偶联，构建磁共振靶向成像及靶向治疗的双功能分子探针（EGFR-USPIO-Gemcitabine）；在体外实验的基础上，依托人胰腺癌裸鼠原位模型，探讨该双功能分子探针对胰腺癌的靶向成像和靶向治疗的机制；进一步增加抗纤维化药物吡菲尼酮，对裸鼠原位胰腺癌进行联合用药的疗效可视化评估。本项目的开展, 有望突破胰腺癌临床治疗的瓶颈，对于提高人口健康水平和人民生活质量具有迫切的现实意义和巨大的社会需求。

Although the diagnosis and treatment of various malignant tumors have been significantly improved nowadays, pancreatic cancer remains to be a difficult clinical situation. The current treatment strategy for advanced pancreatic cancer only results in a modest benefit. It is a major challenge for oncologists to make a breakthrough in this poor treatment effect. Targeted drug delivery may shed some lights on the effective treatment of pancreatic cancer. This project aims to conjugate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) with anti-EGFR polypeptide and gemcitabine(a conventional chemotherapy drug for pancreatic cancer) through chemical modification methods. As a result, a theranostic bifunctional molecular probe (EGFR-USPIO-Gemcitabine) for targeted MRI and targeted therapy in pancreatic cancer will be constructed. The ability of targeted imaging and targeted therapy of this probe will be further demonstrated on pancreatic cancer orthotopic nude mouse model. We will also combine the anti- fibrosis drug, pirfenidone, with our theranostic probe to visually evaluate the combined therapy effect of the two medicine on orthotopic nude mouse model. Our project may help to break the bottleneck of pancreatic cancer treatment and will improve the health level of the people.